S R Shulman, W Gouveia. Show Affiliations »
Abstract
Mesh: See more » Cost-Benefit AnalysisHumansPharmacy and Therapeutics CommitteeTherapeutic Equivalency
Year: 1993 PMID: 10146988 DOI: 10.2165/00019053-199303040-00001
Source DB: PubMed Journal: Pharmacoeconomics ISSN: 1170-7690 Impact factor: 4.981